Bentley Systems Releases Open-Source Library: iModel.js
17.10.2018 11:58:00 EEST | Business Wire | Press release
Bentley Systems, Incorporated, the leading global provider of comprehensive software solutions for advancing the design, construction, and operations of infrastructure, today announced the initial release of its iModel.js library, an open-source initiative to improve the accessibility, for both visualization and analytical visibility, of infrastructure digital twins. iModel.js can be used by developers and IT professionals to quickly and easily create immersive applications that connect their infrastructure digital twins with the rest of their digital world. iModel.js is the cornerstone of Bentley’s just-announced iTwin™ Services that combine iModelHub, reality modeling, and web-enabling software technologies within a Connected Data Environment (CDE) for infrastructure engineering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005008/en/
Bentley Systems Releases Open-Source Library: iModel.js.(Photo: Business Wire)
Bentley’s iModels have become a de facto standard for visibility into digital engineering models. iModelHub manages an iModel as a distributed database with an intrinsic ledger of changes—enabling alignment, accountability, and accessibility of its digital components—to form the backbone of an infrastructure digital twin.
The iModel.js library is a comprehensive collection of JavaScript packages that build on the most open, popular, and flexible standards for modern cloud and web development. It is written in TypeScript, and leverages open technologies including SQLite, Node.js, NPM, WebGL, Electron, Docker, Kubernetes, and of course HTML5 and CSS. The same codebase can produce cloud services and web, mobile, and desktop applications. The source code is hosted on GitHub and is distributed under the MIT license.
With iModel.js, it is simple to create a web-based experience that shows interactive “nD” views (1D, 2D, 3D, 4D, etc.) of iModels that are assembled and synchronized from BIM files and other digital engineering models, and from data created directly with iModel.js. Those same views can also include digital (reality) context, real-time sensor data, and other data from enterprise sources and analytics. Since the iModel is synchronized by iModelHub, it always reflects the most recent updates from all project participants, who are thus able to visualize and analyze changes between points in time or between versions. Importantly, only users and applications authorized by the iModel owner, through iModelHub, are granted access through iModel.js.
Johan Palm, program manager – Digital Project Delivery at Hatch, said, “iModel.js gives Hatch the ability to implement a stakeholder engagement technology that extends the iModelHub visionary technology. We can expose complex project information to a level that is accessible, consumable, and extendable via the cloud and in context to the 3D model. Most importantly we can do so in a manner that embraces change as the project progresses. iModel.js aligns with Hatch’s internal development strategies as it is built on modern, highly portable web technology. Bentley is a key software technology partner on Hatch projects globally where our main objective is to provide a positive impact to our client’s assets and operations.”
Cai Chengguo, chair and general manager, Shenzhen Expressway Consulting Group, said, “The digital twin powered by iModelHub is efficiently improving project management, substantially reducing the waste of resources caused by site problems and will achieve digital handover after completion of the project for visual operations and maintenance.”
Keith Bentley, Bentley Systems’ founder and CTO, said, “We firmly believe that iModel.js, and of course the foundation upon which it is built, is the most open, productive, intuitive, and powerful development environment for capital projects and infrastructure assets, ever. We’re excited to work with user organizations, strategic partners, and third-party developers to build an open ecosystem around iModels to tap the vast potential of infrastructure digital twins. With iModel.js, the well-refined techniques of mainstream cloud and web development can leverage the physical and virtual reality in digital twins with near-zero impedance. By open-sourcing the libraries we use to create our iTwin™ cloud services, we expect to foster a substantial and vibrant ecosystem of innovation.”
More about iModel.js: iModeljs.org.
More about iModels and iModelHub: iModelHub.com.
About Bentley Systems
Bentley Systems is the leading global
provider of software solutions to engineers, architects, geospatial
professionals, constructors, and owner-operators for the design,
construction, and operations of infrastructure. Bentley’s MicroStation-based
engineering and BIM applications, and its digital twin cloud services,
advance the project delivery (ProjectWise) and the asset
performance (AssetWise) of transportation and other public works,
utilities, industrial and resources plants, and commercial and
institutional facilities.
Bentley Systems employs more than 3,500 colleagues, generates annual
revenues of $700 million in 170 countries, and has invested more than $1
billion in research, development, and acquisitions since 2012. From
inception in 1984, the company has remained majority-owned by its five
founding Bentley brothers. Bentley shares transact by invitation on the
NASDAQ Private Market; strategic partner Siemens AG has accumulated a
non-voting minority stake
www.bentley.com
Bentley, the Bentley logo, AssetWise, Connected Data Environment, iTwin, MicroStation, and ProjectWise are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005008/en/
Contact information
Press:
Bentley Systems
Jennifer Maguire
+1 610 458 2695
jennifer.maguire@bentley.com
Follow
us on Twitter: @BentleySystems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
